Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 2;11(7):631.
doi: 10.3390/jpm11070631.

Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer

Affiliations

Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer

Emily P Slater et al. J Pers Med. .

Abstract

Familial pancreatic cancer (FPC) is an established but rare inherited tumor syndrome that accounts for approximately 5% of pancreatic ductal adenocarcinoma (PDAC) cases. No major causative gene defect has yet been identified, but germline mutations in predisposition genes BRCA1/2, CDKN2A and PALB2 could be detected in 10-15% of analyzed families. Thus, the genetic basis of disease susceptibility in the majority of FPC families remains unknown. In an attempt to identify new candidate genes, we performed whole-genome sequencing on affected patients from 15 FPC families, without detecting BRCA1/2, CDKN2A or PALB2 mutations, using an Illumina based platform. Annotations from CADD, PolyPhen-2, SIFT, Mutation Taster and PROVEAN were used to assess the potential impact of a variant on the function of a gene. Variants that did not segregate with pancreatic disease in respective families were excluded. Potential predisposing candidate genes ATM, SUFU, DAB1, POLQ, FGFBP3, MAP3K3 and ACAD9 were identified in 7 of 15 families. All identified gene mutations segregated with pancreatic disease, but sometimes with incomplete penetrance. An analysis of up to 46 additional FPC families revealed that the identified gene mutations appeared to be unique in most cases, despite a potentially deleterious ACAD9 Ala326Thr germline variant, which occurred in 4 (8.7%) of 46 FPC families. Notably, affected PDAC patients within a family carried identical germline mutations in up to three different genes, e.g., DAB1, POLQ and FGFBP3. These results support the hypothesis that FPC is a highly heterogeneous polygenetic disease caused by low-frequency or rare variants.

Keywords: WGS; familial pancreatic cancer; genetic variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
FPC family with an ATM germline variant. The arrow designates the index patient. Diagonal lines indicate deceased individuals.
Figure 2
Figure 2
FPC family with SUFU and FANCM germline variants. Diagonal lines indicate deceased individuals.
Figure 3
Figure 3
FPC family with variants in DAB1, PolQ and FGFBP3 genes. Diagonal lines indicate deceased individuals.
Figure 4
Figure 4
FPC family with MAP3K3 and ACAD9 germline variants. Diagonal lines indicate deceased individuals.
Figure 5
Figure 5
FPC family with a germline ACAD9 A326T variant. Diagonal lines indicate deceased individuals.

References

    1. Quante A.S., Ming C., Rottmann M., Engel J., Boeck S., Heinemann V., Westphalen C.B., Strauch K. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5:2649–2656. doi: 10.1002/cam4.767. - DOI - PMC - PubMed
    1. Bartsch D.K., Kress R., Sina-Frey M., Grützmann R., Gerdes B., Pilarsky C., Heise J.W., Schulte K.-M., Colombo-Benkmann M., Schleicher C., et al. Prevalence of familial pancreatic cancer in Germany. Int. J. Cancer. 2004;110:902–906. doi: 10.1002/ijc.20210. - DOI - PubMed
    1. Bartsch D.K., Gress T., Langer P. Familial pancreatic cancer—current knowledge. Nat. Rev. Gastroenterol. Hepatol. 2012;9:445–453. doi: 10.1038/nrgastro.2012.111. - DOI - PubMed
    1. Canto M.I., Harinck F., Hruban R.H., Offerhaus G.J., Poley J.-W., Kamel I., Nio Y., Schulick R.S., Bassi C., Kluijt I., et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2012;62:339–347. doi: 10.1136/gutjnl-2012-303108. - DOI - PMC - PubMed
    1. Bartsch D.K., Matthäi E., Mintziras I., Bauer C., Figiel J., Sina-Boemers M., Gress T.M., Langer P., Slater E.P. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—knowledge gained in 20 years. Dtsch. Aerzteblatt. 2021;18:163–168. - PMC - PubMed